AFM
AVIR icon

Anson Funds Management’s Atea Pharmaceuticals AVIR Stock Holding History

Anson Funds Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-50,000
Closed -$150K – 172
2023
Q3 		$150K Hold
50,000
– – 0.03% 122
2023
Q2 		$187K Buy
+50,000
New +$187K 0.03% 131
2022
Q1 		– Sell
-53,340
Closed -$477K – 347
2021
Q4 		$477K Buy
+53,340
New +$831K 0.05% 252

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Anson Funds Management's AVIR Position: Q4 2023 in Review

Anson Funds Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 50,000 shares — an estimated $150K sold.

Anson Funds Management first reported a position in AVIR in Q4 2021 and held it in 3 quarters. The position peaked at $477K in Q4 2021. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

  • Anson Funds Management reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Anson Funds Management sold 50,000 Atea Pharmaceuticals shares in Q4 2023, an estimated $150K.
  • Anson Funds Management first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Anson Funds Management's Atea Pharmaceuticals position peaked at $477K in Q4 2021.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on Anson Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.